Novartis Pharma AG: Novartis receives European Commission approval for Cosentyx in polymyalgia rheumatica (PMR)

Cosentyx (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,1 a common inflammatory rheumatic disease with limited advanced treatment options2-6Approval ba...
This is a short summary. The full story is published by Finanznachrichten.de.
Read full story at Finanznachrichten.de


